Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 577 participants.
Also called NCT03191396
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 577 participants
- Sponsor
- Registry
-
NCT03191396 -
2016-004965-22
-
- Other papers using this trial's data
- Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Bulgaria, Czechia, Finland, France, Germany, Hungary, Italy, Poland, Slovenia, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03191396. Randomized; no masking; primary purpose treatment. Start 2017-06-27 (actual); primary completion 2018-07-09 (actual). Results posted on 2019-08-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
- Acronym
- SUSTAIN 10
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Liraglutide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03191396- Content hash
51aaac0215a16f76f961fcf69660a261941c1112e57924e59d4c4d9f1e63683e